H3N2 M2SR influenza vaccine - FluGen

Drug Profile

H3N2 M2SR influenza vaccine - FluGen

Alternative Names: H3N2 M2SR Monovalent Influenza Vaccine; H3N2 viral vaccine - FluGen; Redee Flu; RedeeFlu

Latest Information Update: 26 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FluGen
  • Class Influenza A vaccines; Vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H3N2 subtype

Most Recent Events

  • 18 Oct 2017 FluGen plans phase II trials for Influenza-A virus H3N2 subtype (Prevention) in 2018
  • 29 Jun 2016 Phase-I clinical trials in Influenza-A virus H3N2 subtype (Prevention) in USA (Intranasal) (NCT02822105)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top